Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
WiSP Wissenschaftlicher Service Pharma GmbH
With
Ludwig-Maximilians - University of Munich
Chugai Pharma GmbH
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Presence of histologically proven lymphoproliferative disease specified as Hodgkin's disease, non-Hodgkin's lymphoma (NHL) or multiple myeloma
Indication of high-dose therapy and autologous peripheral blood stem cell transplantation
Availability of a sufficient amount of blood stem cells (CD34+ cells \>= 2.0 x 106/kg)
Age between 18 and 70 years
High-dose therapy with one of the following high-dose regimes: Melphalan 140 mg/m2 or 200 mg/m2, BEAM, BEAC, BUCY or CBV (the last permitted according to amendment 2, see Section 9.8.1)
Patient's written consent to participation in this trial
You may not be if
Previous high-dose therapy and blood stem cell transplantation except for melphalan 140 mg/m2 or 200 mg/m2 in patients with multiple myeloma who did not participate in the cytocapacity test previously (according to amendment 2, see Section 9.8.1).
Known intolerance to lenograstim
Out-patient therapy following high-dose therapy and blood stem cell transplantation
Myocardial infarction \< 6 months prior to inclusion into the study
